RJA
NRIX icon

Raymond James & Associates’s Nurix Therapeutics NRIX Stock Holding History

Raymond James & Associates’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-101,006
Closed -$1.04M – 3995
2023
Q4 		$1.04M Buy
101,006
+3,018
+3% +$20.7K ﹤0.01% 2490
2023
Q3 		$770K Buy
97,988
+5,547
+6% +$50.6K ﹤0.01% 2622
2023
Q2 		$923K Buy
92,441
+24,430
+36% +$249K ﹤0.01% 2525
2023
Q1 		$604K Buy
68,011
+16,980
+33% +$177K ﹤0.01% 2805
2022
Q4 		$560K Sell
51,031
-48
-0.1% -$579 ﹤0.01% 2823
2022
Q3 		$666K Buy
51,079
+9,800
+24% +$155K ﹤0.01% 2657
2022
Q2 		$523K Buy
+41,279
New +$468K ﹤0.01% 2889

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Raymond James & Associates's NRIX Position: Q1 2024 in Review

Raymond James & Associates sold out of Nurix Therapeutics (NRIX) in Q1 2024, closing a stake of 101,006 shares — an estimated $1.04M sold.

Raymond James & Associates first reported a position in NRIX in Q2 2022 and held it in 7 quarters. The position peaked at $1.04M in Q4 2023. 139 funds tracked by Wall St. Rank hold NRIX as of Q1 2024.

  • Raymond James & Associates reported no remaining Nurix Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 101,006 Nurix Therapeutics shares in Q1 2024, an estimated $1.04M.
  • Raymond James & Associates first reported a position in Nurix Therapeutics in Q2 2022 and held it in 7 quarters.
  • Raymond James & Associates's Nurix Therapeutics position peaked at $1.04M in Q4 2023.
  • 139 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.